Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.

Check also Companies to Follow in 2022 and CMN Markets for the latest stock and market trends.

Always stay updated with the free CMN Newsletter.

Excision BioTherapeutics

Main focus: Gene editing for the treatment of viral infections

Company stage: Pre-clinical

Diseases: HIV-1 infection/AIDS, progressive multifocal leukoencephalopathy (PML), Herpes simplex virus (HSV) infection, hepatitis B virus (HBV) infection

Genome editing tool: CRISPR-Cas9, CRISPR-CasX

Funding stage: Private

Location: San Francisco, CA, USA



Excsision BioTherapeutics is a start-up gene-editing company focused on curing viral infections with CRISPR. The company has developed a proprietary technolegy where dual gRNAs excise large sections of viral DNA, eliminating viral escape and reproduction. Its lead programme, EBT-101, is being developed to destroy the human immunodeficiency virus (HIV), to ultimately cure infection by the virus. Other programmes focus on eliminating viruses such as herpex simplex virus and hepatitis B virus.


HashtagExcision BioTherapeutics

Company: Excision BioTherapeutics
Jobs, banner ads, webinars, sponsored content...
Search CRISPR Medicine